Organisation paid for research Program year 2025 Source: CMS Open Payments

Zangmeister Center

Neither a doctor nor a teaching hospital

Research payments

$44,241

19 payments

Through program year 2025, Zangmeister Center is reported as receiving $44,241 in research payments, across 19 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $9,750 1
2024 Research $1,710 3
2023 Research $2,525 2
2022 Research $10,256 3
2021 Research $17,483 4
2020 Research $1,850 3
2019 Research $666 3

Breakdown

Who paid Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $28,052 7 payments
  2. Celgene Corporation $16,135 10 payments
  3. Incyte Corporation $54 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Connect MM- The Multiple Myeloma Disease Registry $11,250 3 payments
  2. Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients. $9,750 1 payment
  3. A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen $9,526 2 payments
  4. A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma $7,954 2 payments
  5. Connect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry: The purpose of the Connect Myeloid disease registry is to provide unique insights into treatment decisions and tr $1,875 1 payment
  6. A Phase 3B Randomized Study of Lenalidomide (CC-50 $860 2 payments
  7. Celgene - Connect MDS/AML $750 1 payment
  8. A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma $650 1 payment
  9. A Phase 3, Randomized, Open Label Trial of LenalidomideDexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma $612 1 payment
  10. Connect MDS/AML $375 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record